Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Human immunodeficiency virus type 1 integrase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Trypanosoma brucei | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Plasmodium yoelii | integrase-related | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma congolense | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.074 | 0.0961 | 0.0961 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.2604 | 0.5579 | 0.5 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.2604 | 0.5579 | 0.5 |
Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.4389 | 1 | 1 |
Echinococcus granulosus | dihydrofolate reductase | 0.4389 | 1 | 1 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.2604 | 0.5579 | 0.5 |
Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.4389 | 1 | 1 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.2604 | 0.5579 | 0.5 |
Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.4389 | 1 | 1 |
Brugia malayi | thymidylate synthase | 0.074 | 0.0961 | 0.0961 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.2604 | 0.5579 | 1 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.2604 | 0.5579 | 0.5 |
Schistosoma mansoni | dihydrofolate reductase | 0.4389 | 1 | 1 |
Echinococcus multilocularis | dihydrofolate reductase | 0.4389 | 1 | 1 |
Chlamydia trachomatis | dihydrofolate reductase | 0.4389 | 1 | 0.5 |
Loa Loa (eye worm) | dihydrofolate reductase | 0.4389 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0352 | 0 | 0.5 |
Onchocerca volvulus | 0.074 | 0.0961 | 0.5 | |
Brugia malayi | Dihydrofolate reductase | 0.4389 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (functional) | = 29.04 uM | Cytotoxic concentration required to reduce MT-4 cell viability | ChEMBL. | 16250669 |
CC50 (functional) | = 29.04 uM | Cytotoxic concentration required to reduce MT-4 cell viability | ChEMBL. | 16250669 |
EC50 (functional) | = 6.07 uM | Effective concentration required to reduce HIV-1-induced cytopathic effect in MT-4 cells | ChEMBL. | 16250669 |
IC50 (binding) | = 0.15 uM | In vitro concentration required to inhibit the overall HIV-1 integrase strand transfer | ChEMBL. | 16250669 |
IC50 (binding) | = 0.15 uM | In vitro concentration required to inhibit the overall HIV-1 integrase strand transfer | ChEMBL. | 16250669 |
IC50 (binding) | = 0.68 uM | In vitro concentration required to inhibit the HIV-1 integrase strand transfer | ChEMBL. | 16250669 |
IC50 (binding) | = 0.68 uM | In vitro concentration required to inhibit the HIV-1 integrase strand transfer | ChEMBL. | 16250669 |
IC50 (binding) | = 162.5 uM | In vitro concentration required to inhibit the HIV-1 integrase 3' strand transfer | ChEMBL. | 16250669 |
IC50 (binding) | = 162.5 uM | In vitro concentration required to inhibit the HIV-1 integrase 3' strand transfer | ChEMBL. | 16250669 |
Selectivity index (functional) | = 5 uM | Selectivity index was measured by the ratio of CC50/EC50 | ChEMBL. | 16250669 |
Selectivity index (functional) | = 5 uM | Selectivity index was measured by the ratio of CC50/EC50 | ChEMBL. | 16250669 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.